SCHEMBL2263564

SCHEMBL2263564

Cc1ccc(Cn2c(-c3ccccc3)cc(C(F)(F)F)c(CN(C)C)c2=O)c(C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 3/20 0.40
NR1H3 Q13133 3/20 0.40
RXRA P19793 2/20 0.40
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38
CNR1 P21554 1/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2B Q13224 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.34
HTT P42858 2/20 0.34
LMNA P02545 1/20 0.34
RAB9A P51151 1/20 0.34
BCL2 P10415 1/20 0.34
MCL1 Q07820 1/20 0.34
ALDH1A1 P00352 4/20 0.33
KDM4E B2RXH2 3/20 0.33
MAPT P10636 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2264665 0.92 NR1H2 (0.51) NR1H2NR1H3RXRACYP1A2CYP2D6
SCHEMBL12366588 0.88 NR1H2 (0.41) NR1H2NR1H3RXRACNR1GRIN2B
Hydrochloric Acid SCHEMBL2263835 0.87 NR1H2 (0.40) NR1H2NR1H3RXRACNR1GRIN2B
SCHEMBL12390337 0.85 NR1H2 (0.39) NR1H2NR1H3RXRAHPGDCNR1
SCHEMBL12390431 0.84 NPC1 (0.42) NR1H2NR1H3RXRALMNARAB9A
SCHEMBL4904530 0.84 RXRA (0.57) NR1H2NR1H3RXRAALDH1A1KDM4E
SCHEMBL12366953 0.83 FPR1 (0.36) NR1H2NR1H3CYP1A2CYP2C9HPGD
SCHEMBL4897287 0.83 KDM4E (0.52) NR1H2NR1H3RXRAHPGDSMN1; SMN2
SCHEMBL2263811 0.81 NR1H2 (0.59) NR1H2NR1H3RXRAHPGDLMNA
SCHEMBL14944178 0.81 EPHX2 (0.44) HPGDSMN1; SMN2RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7998986-B2 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
US-7998986-B2 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
US-7998986-B2 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
EP-1465869-A4 MODULATORS OF LXR X CEPTOR THERAPEUTICS INC (US) 2005-12-28 EP disclosed
EP-1465869-A1 MODULATORS OF LXR X-Ceptor Therapeutics, Inc. (US) 2004-10-13 EP disclosed
US-20030181420-A1 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS, INC. 2003-09-25 US disclosed
WO-2003059884-A1 MODULATORS OF LXR X-CEPTOR THERAPEUTICS, INC. (US) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181420-A1 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors NR1H2, NR1H3, NCOA1 NR1H2 1/4885NR1H3 2/4885RXRA 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.